March 18, 2021
Here is the article.
Translate Bio Plummets On Unexpected Testing Flop For mRNA Drug
Translate Bio (TBIO) could be facing a two-year delay for its cystic fibrosis drug, an analyst said Thursday as TBIO stock crashed on an unexpected testing flop.
The company said its inhaled cystic fibrosis treatment proved safe in testing, but failed to improve lung function. The drug uses the same messenger RNA technology that powers highly effective coronavirus vaccines from Pfizer (PFE) and Moderna (MRNA).
On today's stock market, TBIO stock plunged 30.9% to 17.76.
No comments:
Post a Comment